Biovie is trading 5.17% down at $1.10 in pre-market, with no specific catalyst confirmed.
- No company announcement dated October 15 was listed. The latest company news was an October 14 announcement of upcoming presentations of Phase 2 findings at the American Neurological Association meeting, October 17–20.
- The broader backdrop is cautious after hotter-than-expected U.S. inflation and overnight weakness in Asian technology stocks, but available evidence does not directly link those moves to Biovie.